Showing 1-10 of about 26 articles.

Revolution Medicines, Inc.

Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...

January 05, 2021

Blue Star Foods Corp.

Blue Star Foods Corp. Signs Term Sheet to Acquire Taste of BC Aquafarms, Inc.

Acquisition Would Signify a Strategic Investment into the Recirculating Aquaculture Systems (RAS) Industry Miami, Florida, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (OTC: BSFC)...

December 28, 2020

Revolution Medicines, Inc.

Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress

Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination First-in-Class RAS(ON) Inhibitor Programs for Five Targets...

November 12, 2020

Revolution Medicines, Inc.

Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers

Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and...

October 24, 2020

Revolution Medicines, Inc.

Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

REDWOOD CITY, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...

October 12, 2020

Revolution Medicines, Inc.

Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

Presentation at 2nd Annual RAS-Targeted Drug Development Conference Highlights First Publicly Reported Data for Inhibitors of Notorious Cancer Protein KRASG12D(ON) REDWOOD CITY, Calif., Sept. 16,...

September 16, 2020

Revolution Medicines, Inc.

Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference

REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...

September 08, 2020

Revolution Medicines, Inc.

Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined Tumors Targeted Combination Strategy Underpins Initiation of New Clinical...

August 10, 2020

Revolution Medicines, Inc.

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive...

July 13, 2020

Revolution Medicines, Inc.

Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock

REDWOOD CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock...

July 08, 2020

Showing 1-10 of about 26 articles.

Search Results

Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference

Blue Star Foods Corp. Signs Term Sheet to Acquire Taste of BC Aquafarms, Inc.

Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress

Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers

Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference

Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock

Newswire Distribution Network & Management

About Us